We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > RSVI-301

News List

The world's first-in-class miRNA therapeutics to cure diabetes by pancreatic beta cell regeneration prnasia
May 07, 2021
Nexturn Bio Inc., a subsidiary of Nexturn Bioscience Co., Ltd., has selected its first technological investment target to expand its new bio business.
Nexturn Bio Inc. decided to invest in the development of a new drug pipeline for diabetes treatment using miRNA prnasia
May 07, 2021
Nexturn Bio Inc., a subsidiary of Nexturn Bioscience Co., Ltd., said it has secured a 50% stake in RosVivo Therapeutics Inc., a U.S. new drug developer, as its first investment destination. RosVivo recently developed RSVI-301, a new drug pipeline that ...